loading...| Preferred Name | aprepitant | |
| Synonyms |
Emend ONO-7436 L-754030 MK-0869 |
|
| Definitions |
A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49173" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49173" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000454517 |
|
| altLabel |
Emend ONO-7436 L-754030 MK-0869 |
|
| cui |
C1176306 C1175300 C1706844 C0759820 C0757679 |
|
| DATE FIRST PUBLISHED |
2005-11-04 |
|
| Date last modified |
2008-03-03 |
|
| definition |
A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49173" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49173" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C49173 |
|
| notation |
CDR0000454517 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
aprepitant |
|
| tui |
T109 T121 |